Gilead seeks US approval of sofosbuvir in HCV
This article was originally published in Scrip
Executive Summary
Gilead Sciences is seeking approval from the US FDA to market sofosbuvir, a once-daily oral nucleotide analogue inhibitor, as a treatment for chronic hepatitis C virus (HCV) infection, the leading cause of liver cancer and liver transplantation in the US – affecting up to 4 million Americans.